COSCIENS Biopharma Inc (CSCI) NPV

Sell:4.90 CADBuy:5.01 CADNo change

Prices delayed by at least 15 minutes
Sell:4.90 CAD
Buy:5.01 CAD
Change:No change
Prices delayed by at least 15 minutes
Sell:4.90 CAD
Buy:5.01 CAD
Change:No change
Prices delayed by at least 15 minutes

Company Information

About this company

COSCIENS Biopharma Inc. is a Canada-based life science company. The Company is developing and commercializing a diversified portfolio of products for the cosmeceutical, nutraceutical and pharmaceutical markets. The Company’s patented technologies include the Pressurized Gas eXpanded (PGX) technology, which is a technology that generates high-value yields of active ingredients from natural-based resources for use in novel cosmeceutical, nutraceutical and pharmaceutical products. The Company's two products, oat beta glucan and avenanthramides, are found in household-name cosmetic and personal care brands. These products are manufactured from the Company’s proprietary oat extraction manufacturing technology and are known for their well-documented health benefits. Its lead product, macimorelin (Macrilen; Ghryvelin), is the oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD).

Key people

Ronald W. Miller
Chairman of the Board
Anna Biehn
Chief Executive Officer
Giuliano La Fratta
Chief Financial Officer, Senior Vice President, Director
Genevieve Foster
Director
Gilles R. Gagnon
Director
Ulrich Kosciessa
Director
William W. Li
Director
Dennis Turpin
Independent Director
Click to see more

Key facts

  • EPIC
    CSCI
  • Location
    Canada
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    CA22112H1010
  • Market cap
    CA$16.09m
  • Employees
    21
  • Shares in issue
    3.15m
  • Exchange
    Toronto Stock Exchange
  • Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.